Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07782164 | Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)(PELFIRE) | recruiting | — | 27 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793318 | TR115 in ARID1A-Mutated Advanced Solid Tumors | not yet recruiting | Phase 2 | 50 | Tarapeutics Science Inc.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793552 | Needlefree Lidocaine Application for Vulvar Biopsies | not yet recruiting | N/A | 106 | Tufts Medical CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04878094 | A Study of Intra-operative Imaging in Women With Ovarian Cancer | active not recruiting | Phase 3 | 155 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06492070 | Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | recruiting | Phase 2 | 70 | Emory UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07078409 | Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology | enrolling by invitation | N/A | 240 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07125209 | Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers | recruiting | — | 18 | University of Wisconsin, MadisonOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | recruiting | Phase 1 | 200 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07544680 | Endometrial Cancer Vaginal Fluid Specimen Collection Study(ENVISION) | recruiting | — | 4,200 | Exact Sciences CorporationINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07790939 | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer | not yet recruiting | Early Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT04034927 | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | active not recruiting | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04329494 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | recruiting | Phase 1 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05053230 | A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer(IMPROVE) | active not recruiting | N/A | 324 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | recruiting | Phase 3 | 186 | Genelux CorporationINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07349641 | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 90 | Cogent Biosciences, Inc.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT04847063 | Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05483491 | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | recruiting | Phase 1 | 30 | Christian HinrichsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT07771400 | Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients(MOANA) | not yet recruiting | — | 320 | Latin American Cooperative Oncology GroupOTHER | 4 | Aug 25, 2026 | clinicaltrials |
| NCT07779109 | Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)(PURE-cohort) | recruiting | N/A | 50 | Instituto de Investigación Sanitaria AragónOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Mayo ClinicOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05074264 | Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico(CAMPO-101) | active not recruiting | N/A | 1,586 | University of California, San FranciscoOTHER | 2 | Aug 24, 2026 | clinicaltrials |
| NCT06459271 | Feasibility of CALM in Patients With Ovarian Cancer | recruiting | N/A | 50 | University Health Network, TorontoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer(MELIA) | not yet recruiting | Phase 2 | 128 | Tongji HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781475 | Spatially Fractionated Radiation Therapy for Locally Advanced Cervical Cancer(SFRT-LACC) | not yet recruiting | N/A | 126 | The University of Hong Kong-Shenzhen HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07782697 | Postoperative ctHPV-DNA for Recurrence Prediction and Adjuvant Treatment Decision-Making in Cervical Cancer | not yet recruiting | — | 580 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07783022 | Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer | recruiting | — | 1,920 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | active not recruiting | Phase 3 | 450 | National Cancer Institute (NCI)NIH | 3 | Aug 21, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04310826 | Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy | active not recruiting | N/A | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05548296 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | recruiting | Phase 2 | 350 | Acrivon TherapeuticsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06365853 | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | active not recruiting | Phase 2 | 108 | AbbVieINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT06468215 | Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer | recruiting | N/A | 16 | Peking University People's HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors(LNCB74-01) | recruiting | Phase 1 | 145 | NextCure, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07524114 | Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)(SHERLOCK) | recruiting | — | 7,000 | University Health Network, TorontoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07778498 | A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 150 | Phrontline BiopharmaINDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07779538 | Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 420 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07780019 | Microwave Ablation of Uterine Fibroids(MyoMwa) | active not recruiting | — | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03355976 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | active not recruiting | Phase 2 | 46 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04569773 | Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer | active not recruiting | — | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04596384 | Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery | active not recruiting | N/A | 398 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2026source: clinicaltrials